Lupin gets thumbs up from USFDA to market generic medication in US

Posted on by

Pharmaceutical company Lupine said on Friday that its unit has received approval from the US health regulator to market a drug to treat various disorders such as schizophrenia.

Lubin said in a statement that the company’s wholly-owned subsidiary based in Somerset has received US Food and Drug Administration (USFDA) approval for chlorpromazine hydrochloride tablets.

The Mumbai-based drugmaker’s product is the generic version of that of Upsher-Smith Laboratories, LLC.

According to IQVIA MAT data, Chlorpromazine Hydrochloride Tablets have an estimated annual sales of $45 million in the United States.

(Only the title and image for this report may have been reworked by the Business Standard staff; the rest of the content is generated automatically from a shared feed.)

First published: July 14, 2023 | 9:47 p.m ist